RNA-seq of human breast cancer cell line MDA-MB-231 treated with T025 against untreated controls

Deep RNA sequencing was performed to investigate the impact of CLKs inhibitor, T-025, on RNA splicing in triple-negative breast cancer cell lines. A total of 30 million MDA-MB-231 cells were seeded in a 6-well plate. The following day, cells were treated with 1 µM T-025 or 0.1% DMSO as negative control for 24 hours. Samples from 3 biological replicates were used. Total RNA was isolated using the RNeasy plus mini kit (Qiagen). Stranded PolyA-selected libraries were prepared using the DNBseq platform, and 100 M 150-bp paired-end reads were sequenced on a DNBSEQ-G400 sequencer by BGI Europe. The differentially expressed genes (DEGs) and alternative splicing events (ASEs) were analyzed to unravel the transcriptomic changes in TNBC cells upon T-025 treatment.